Negocieri pentru unul dintre cele mai mari acorduri din istoria industriei farmaceutice. AstraZeneca discută preluarea Bristol Myers Squibb

AstraZeneca and Bristol Myers Squibb are in talks for a potential merger that could create a major pharmaceutical entity valued at around $400 billion. Discussions have been ongoing for months, but no final agreement is guaranteed. The merger could strengthen AstraZeneca's position in the U.S. market, although both companies face challenges due to overlapping oncology portfolios and differing growth prospects. AstraZeneca aims for $80 billion in annual sales by 2030, while Bristol Myers Squibb is under pressure from patent expirations. Experts warn that such a merger could slow down drug development despite potential cost savings.